9-ME-BC
9-Me-BC (9-methyl-β-carboline) is a synthetic compound often discussed in nootropic and research contexts for its effects on dopamine-related pathways. It is commonly described as a monoamine oxidase inhibitor (MAOI) in experimental settings and has been explored for potential cognitive or motivational effects. Human data are limited, and safety, dosing, and long-term effects are not well established.
-
This page summarizes anecdotal reports and community observations, not medical evidence. Reports may be incomplete, biased or inaccurate and are not medical advice or recommendations. “Risk” here refers to how frequently severe or prolonged symptom worsening is reported, not to proven causation or population-wide probability. Individual responses vary widely, and absence of issues in some users does not rule out significant reactions in others.
-
Within PFS/PSSD/PAS communities, 9-Me-BC is discussed in relation to its potential interactions with dopaminergic and monoamine signaling pathways. In preclinical research, β-carbolines have been shown to interact with monoamine pathways, including dopaminergic signaling, and some compounds in this class exhibit MAO-inhibiting properties or influence dopaminergic neuron function. Dopamine systems are tightly linked to motivation, reward, libido, emotional salience, and stress reactivity—all domains that are often discussed in relation to PFS / PSSD / PAS. Dopamine systems do not operate in isolation—they interact with serotonin, stress hormones, and neurosteroid/GABA signaling, suggesting possible intersections with pathways that may already be dysregulated in these conditions.
-
Community Reports: Mixed Outcomes & Variable Risk Signal
In PFS/PSSD/PAS discussions, 9-Me-BC is described with high variability but a concerning downside signal. A minority of people report short-term benefits (e.g., increased motivation, mental clarity, or libido responsiveness), but many report no lasting benefit, and a notable subset describe clear worsening. Reported worsening themes include increased anxiety or agitation, emotional blunting or flattening, insomnia, anhedonia, cognitive overstimulation followed by crashes, and a general sense of nervous-system destabilization. Some describe feeling briefly “upregulated” followed by a lower baseline once the compound is stopped. Because many of these reports involve delayed or persistent worsening, 9-Me-BC is often grouped with other high-risk dopaminergic/monoaminergic experiments rather than low-impact supplements.
Evidence Basis: Preclinical literature on β-carbolines and dopaminergic/monoamine systems; general neuropharmacology of dopamine and MAO-related compounds; anecdotal community reports (online forums, self-reports). No controlled human studies establishing safety or efficacy for PFS/PSSD/PAS.
-
Minor Improvement
Crash / Baseline Drop (Reported)
Mixed / No Effect
Public comments reflect individual experiences and opinions. They are not medical advice and may not be accurate or representative.